With the emergence of metallo-betalactamases (MBL) in Pseudomonas aeruginosa (P. aeruginosa), the value of carbapenem, the drug of last resort, is being severely compromised. Curtailing the use of carbapenems becomes paramount if resistance is to be reined in.
What new information is offered in this study?
In this study, levofloxacin with piperacillin-tazobactam emerged as an effective treatment alternative that could be used before carbapenems in the treatment of multidrugresistant strains.
What are the implications for research, policy, or practice?
In multidrug-resistant strains, combination treatment using drugs demonstrating synergy, such as levofloxacin with piperacillin-tazobactam, may be effective in treating patients with multidrug-resistant infections.
Background
Pseudomonas aeruginosa (P. aeruginosa), the most prominent nosocomial pathogen, has intrinsic resistance to many drug classes, along with an ability to acquire resistance to all available treatment options. 1 Primary mechanisms of acquisition of drug resistance include reduced cell permeability, efflux pumps, changes in target enzymes, and inactivation of the antibiotics. 2, 3 No single mutation compromises every antipseudomonal drug. Nevertheless, upregulated efflux systems can simultaneously compromise fluoroquinolones and most ß-lactams, leaving only the aminoglycosides and imipenem (to which mutational resistance evolves at high frequency). The selection of resistant mutants, a risk associated with any antipseudomonal therapy, varies with the type and dosage of antibiotic used and the infection site. 4 Combination therapy is thus used with the aim of expanding the antimicrobial spectrum, minimising toxicity, preventing the emergence of resistant mutants during therapy, and obtaining synergistic antimicrobial activity.
5,6
The checkerboard titration method and the time-kill curve technique have been the most commonly used methods to determine synergism.
7-9

Method
The study was conducted in the Department of Microbiology, Jawaharlal Nehru Medical College and Hospital, Amu, Aligarh, India, between April 2009 and September 2010. Two-hundred-and-sixty strains of P. aeruginosa from different sources were subjected to antimicrobial sensitivity testing by the Kirby-Bauer disc diffusion method 10 for the following antimicrobial agents:
ceftazidime (30µg), gatifloxacin (5µg), cefepime (30µg), ceftriaxone (30µg), levofloxacin (5µg), cefoperazone (75µg), ceftazidime-clavulanic acid (30/10µg), cefoperazonesulbactam (75/75µg), ticarcillin (75µg), ticarcillin-clavulanic acid (75/10µg), tobramycin (10µg), amikacin (30µg), piperacillin (100µg), piperacillin-tazobactam (100/10µg), and imipenem (10µg). Isolates resistant to ß-lactams, aminoglycosides, and fluoroquinolones were termed multidrug-resistant isolates. Extended spectrum ß-lactamase (ESBL) production was determined by the disc potentiation method.
11
Minimum inhibitory concentration (MIC) was estimated for 60 representative isolates of differing levels of drug resistance for three drugs, namely, cefoperazone-sulbactam (Cfs) by E-test (Hi-Media), 10 and for levofloxacin (Le) and piperacillin-tazobactam (Pt) by the standard broth dilution method. 10 Accordingly, these isolates were divided into three groups based on their resistance pattern to different classes of antimicrobials-i.e., aminoglycosides (amikacin), ß-lactams (piperacillin), ß-lactams with inhibitors (cefoperazone-sulbactam), and fluoroquinolones (levofloxacin)-as follows:
 Group 1 consisted of those isolates that were resistant to all four groups of antimicrobials and comprised 10 isolates.
 Group 2 consisted of those isolates that were resistant to any three groups of antimicrobials and comprised 20 isolates.
 Group 3 consisted of those isolates that were resistant to any one or two group of antimicrobials and comprised 30 isolates.
Synergy testing by chequerboard and time-kill assays was performed for two combinations of antimicrobials as follows: piperacillin-tazobactam with levofloxacin (11 isolates), and cefoperazone-sulbactam with levofloxacin (10 isolates). Chequerboard synergy was performed as described previously. 10 Fractional inhibitory concentrations Isolates were tested for synergy between levofloxacin and piperacillin-tazobactam and levofloxacin and cefoperazonesulbactam by time-kill assay as described by Hayami et al. 12 Viable counts were performed at 0, 2, 4, and 24 hours. Concentration of the combined MICs were as follows; ¼A+ ¼B, ¼A+2B, 2A+ ¼B, 2A+2B. Synergy was defined as ≥3 log10 decrease in colony count at 24 hours by the combination compared to the most active single agent. Indifference was taken as <3 log10 increase or decrease in colony count at 24 hours by the combination compared with that by the most active drug alone, and 3 log10 increase in colony count at 24 hours was taken as antagonism.
Results
Antimicrobial susceptibility of P. aeruginosa strains from specimens is given in Figure 1 . MIC50 of amikacin was 32µg/ml and MIC90 was 64µg/ml. MIC50 and MIC90 of cefoperazone-sulbactam was 32µg/ml and 64µg/ml, and for levofloxacin it was 10µg/ml and 240µg/ml, respectively, while piperacillin-tazobactam has MIC50 and MIC90 of 5µg/ml and 10µg/ml. 12 However, the intensive use of antimicrobials inevitably leads to the appearance of strains resistant to these drugs. In our study, out of the various groups tested, most (85.2 per cent) P. aeruginosa strains were susceptible to antipseudomonal penicillins with inhibitors, followed by antipseudomonal penicillins (70.4 per cent).
Out of a total of 260 P. aeruginosa isolates, 27.3 per cent were found to be multidrug resistant and 19.6 per cent were ESBL producers. Other authors have reported MDR in nearly 45 per cent of P. aeruginosa isolates and 25 per cent isolates as ESBL producers. 18 Carbapenems are the only treatment option for such isolates. However, the emergence of carbapenem-resistant P. aeruginosa strains due the transmission of plasmid mediated metallo-betalactamases has become a challenge for clinicians and microbiologists.
Despite the intensive research in many pharmaceutical industries, no novel class of antibiotic, which resolves the problem of antimicrobial resistance, has been introduced into medical practice. 19 Under these circumstances, combination therapy, employing pre-existing antibiotics, seems a plausable alternative approach for the treatment of infections due to multidrug-resistant strains.
The chequerboard titration method and the time-kill curve technique have been the methods most commonly used to determine in-vitro antibiotic interactions. [20] [21] [22] Although each method uses different conditions and end points, there is frequent agreement between the results of the two methods. 23 In our study, the concordance between these two methods was 71.4 per cent. Other authors have reported agreement between 72-81 per cent. 24 The results of this study demonstrate that the combination of piperacillintazobactam and levofloxacin achieve in-vitro synergy in 72.7 per cent of P. aeruginosa isolates. In contrast, levofloxacin and cefoperazone-sulbactam combination was synergistic in just 30 per cent of the tested isolates. Synergy was surprisingly not apparent when strains were susceptible to the combination drugs, however, synergy was observed when strains were resistant to one or both the agents. The potential of levofloxacin to act synergistically with piperacillin-tazobactam against resistant isolates may prove advantageous when selecting antimicrobial therapy in institutions with high rates of drug resistance among P. aeruginosa.
Conclusion
Synergistic combinations of drugs that are a suitable alternative to carbepenems are required because of the necessity to provide effective, first-line drug treatment options. In this study, Le-Pt emerged as an option for the treatment of multidrug-resistant P. aeruginosa infections, and as such could be an alternative therapy before treatment using carbapenems. 
